Literature DB >> 7477288

Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide.

M J Lopez1, S K Wong, I Kishimoto, S Dubois, V Mach, J Friesen, D L Garbers, A Beuve.   

Abstract

Around half of all humans with essential hypertension are resistant to salt (blood pressure does not change by more than 5 mm Hg when salt intake is high), and although various inbred strains of rats display salt-insensitive elevated blood pressure, a gene defect to account for the phenotype has not been described. Atrial natriuretic peptide (ANP) is released from the heart in response to atrial stretch and is thought to mediate its natriuretic and vaso-relaxant effects through the guanylyl cyclase-A receptor (GC-A). Here we report that disruption of the GC-A gene results in chronic elevations of blood pressure in mice on a normal salt diet. Unexpectedly, the blood pressure remains elevated and unchanged in response to either minimal or high salt diets. Aldosterone and ANP concentrations are not affected by the genotype. Therefore, mutations in the GC-A gene could explain some salt-resistant forms of essential hypertension and, coupled with previous work, further suggest that the GC-A signaling pathway dominates at the level of peripheral resistance, where it can operate independently of ANP.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7477288     DOI: 10.1038/378065a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  133 in total

1.  Three dimensional atomic model and experimental validation for the ATP-Regulated Module (ARM) of the atrial natriuretic factor receptor guanylate cyclase.

Authors:  T Duda; P Yadav; A Jankowska; V Venkataraman; R K Sharma
Journal:  Mol Cell Biochem       Date:  2001-01       Impact factor: 3.396

2.  Alternative splicing for the alpha1 subunit of soluble guanylate cyclase.

Authors:  D Ritter; J F Taylor; J W Hoffmann; L Carnaghi; S J Giddings; H Zakeri; P Y Kwok
Journal:  Biochem J       Date:  2000-03-15       Impact factor: 3.857

3.  Three dimensional atomic model and experimental validation for the ATP-Regulated Module (ARM) of the atrial natriuretic factor receptor guanylate cyclase.

Authors:  T Duda; P Yadav; A Jankowska; V Venkataraman; R K Sharma
Journal:  Mol Cell Biochem       Date:  2000-11       Impact factor: 3.396

4.  Natriuretic peptide receptors and the heart.

Authors:  L King; M R Wilkins
Journal:  Heart       Date:  2002-04       Impact factor: 5.994

5.  Temperature has a major influence on cardiac natriuretic peptide in salmon.

Authors:  V Tervonen; K Kokkonen; H Vierimaa; H Ruskoaho; O Vuolteenaho
Journal:  J Physiol       Date:  2001-10-01       Impact factor: 5.182

6.  A friend within the heart: natriuretic peptide receptor signaling.

Authors:  Jeffery D Molkentin
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

Review 7.  Long-term blood pressure control: is there a set-point in the brain?

Authors:  Yasuhiro Nishida; Megumi Tandai-Hiruma; Takehito Kemuriyama; Kohsuke Hagisawa
Journal:  J Physiol Sci       Date:  2012-05       Impact factor: 2.781

Review 8.  Regulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases.

Authors:  Lincoln R Potter
Journal:  Pharmacol Ther       Date:  2010-12-24       Impact factor: 12.310

9.  The heart communicates with the endothelium through the guanylyl cyclase-A receptor: acute handling of intravascular volume in response to volume expansion.

Authors:  Barbara Schreier; Sebastian Börner; Katharina Völker; Stepan Gambaryan; Stephan C Schäfer; Peter Kuhlencordt; Birgit Gassner; Michaela Kuhn
Journal:  Endocrinology       Date:  2008-05-01       Impact factor: 4.736

10.  Corin variant associated with hypertension and cardiac hypertrophy exhibits impaired zymogen activation and natriuretic peptide processing activity.

Authors:  Wei Wang; Xudong Liao; Koichi Fukuda; Sabine Knappe; Faye Wu; Daniel L Dries; Jun Qin; Qingyu Wu
Journal:  Circ Res       Date:  2008-07-31       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.